SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
19179900
Source:
http://linkedlifedata.com/resource/pubmed/id/19179900
Search
Subject
(
60
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0015133
,
umls-concept:C0030705
,
umls-concept:C0075616
,
umls-concept:C0079083
,
umls-concept:C0149925
,
umls-concept:C0205231
,
umls-concept:C0282460
,
umls-concept:C1516238
pubmed:issue
2
pubmed:dateCreated
2009-1-30
pubmed:abstractText
To assess the efficacy and toxicity of carboplatin, etoposide, and exisulind as initial therapy for extensive stage small cell lung cancer.
pubmed:grant
http://linkedlifedata.com/resource/pubmed/grant/CA31946
,
http://linkedlifedata.com/resource/pubmed/grant/CA33601
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/101274235
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin
,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide
,
http://linkedlifedata.com/resource/pubmed/chemical/Sulindac
,
http://linkedlifedata.com/resource/pubmed/chemical/sulindac sulfone
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1556-1380
pubmed:author
pubmed-author:BaggstromMaria QMQ
,
pubmed-author:Burdette-RadouxSusanS
,
pubmed-author:Cancer and Leukemia Group B
,
pubmed-author:GovindanRamaswamyR
,
pubmed-author:GreenMark RMR
,
pubmed-author:HodgsonLydiaL
,
pubmed-author:VokesEverett EEE
,
pubmed-author:WangXiaofeiX
pubmed:issnType
Electronic
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
220-6
pubmed:meshHeading
pubmed-meshheading:19179900-Adult
,
pubmed-meshheading:19179900-Aged
,
pubmed-meshheading:19179900-Aged, 80 and over
,
pubmed-meshheading:19179900-Antineoplastic Combined Chemotherapy Protocols
,
pubmed-meshheading:19179900-Carboplatin
,
pubmed-meshheading:19179900-Etoposide
,
pubmed-meshheading:19179900-Female
,
pubmed-meshheading:19179900-Humans
,
pubmed-meshheading:19179900-Lung Neoplasms
,
pubmed-meshheading:19179900-Male
,
pubmed-meshheading:19179900-Middle Aged
,
pubmed-meshheading:19179900-Neoplasm Staging
,
pubmed-meshheading:19179900-Prognosis
,
pubmed-meshheading:19179900-Small Cell Lung Carcinoma
,
pubmed-meshheading:19179900-Sulindac
,
pubmed-meshheading:19179900-Survival Rate
,
pubmed-meshheading:19179900-Treatment Outcome
pubmed:year
2009
pubmed:articleTitle
A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.
pubmed:affiliation
Washington University School of Medicine and Alvin J Siteman Cancer Center, St Louis, MO 63110, USA. rgovinda@dom.wustl.edu
pubmed:publicationType
Journal Article
,
Clinical Trial, Phase II
,
Research Support, N.I.H., Extramural